Skip to main content
Wanbury Limited logo

Wanbury Limited — Investor Relations & Filings

Ticker · WANBURY ISIN · INE107F01022 LEI · 335800QB384KGMBID276 BSE.NS Manufacturing
Open in API
Filings indexed 916 across all filing types
Latest filing 2021-09-02 Regulatory Filings
Country IN India
Listing BSE.NS WANBURY

About Wanbury Limited

https://www.wanbury.com

Wanbury Limited specializes in the development and manufacture of Active Pharmaceutical Ingredients (APIs) and finished formulations. The organization maintains a significant global presence, particularly as a leading producer of Metformin. Its product portfolio spans diverse therapeutic areas, including gynecology, orthopedics, hematinics, and anti-diabetics. The company operates manufacturing facilities compliant with international regulatory standards, including the USFDA. Wanbury focuses on providing medicinal solutions through integrated research and development capabilities and large-scale production infrastructure, serving both domestic and international markets with a range of specialty products.

Recent filings

Filing Released Lang Actions
This is to inform you that the 33rd Annual General Meeting of the Members of the Company will be held on Monday, 27th September, 2021 at 11:30 A.M. through Video Conference (VC) or Other ....
Regulatory Filings
2021-09-02 English
Pursuant to Regulation 30 read with Schedule III Para A, of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, and in compliance with relevant circulars issued ....
Regulatory Filings
2021-09-02 English
Board Meeting — Financial Results
Regulatory Filings Classification · 95% confidence The document text contains only placeholders for images and no substantive text or financial data. The true document length is only 113 characters, which is extremely short and does not contain any report content. It is likely a placeholder or an announcement with no detailed information. According to the MENU VS MEAL RULE, such a short document without actual report content should be classified as a Report Publication Announcement (RPA) or Regulatory Filing (RNS). Given the lack of any textual content or indication of report publication, the safest classification is Regulatory Filings (RNS) as a fallback category.
2021-08-09 English
The Board Meeting to be held on 12/08/2021 has been revised to 20/09/2021 The Board Meeting to be held on 12/08/2021 has been revised to 20/09/2021 This is with reference to our ....
Regulatory Filings
2021-08-09 English
Board Meeting — Financial Results
Regulatory Filings Classification · 95% confidence The document text contains only placeholders for images and no substantive text or financial data. The true document length is only 161 characters, indicating it is extremely short and does not contain any report content. There is no indication of report type, financial data, or announcements. Given the lack of content, this document does not fit any specific report category and defaults to Regulatory Filings (RNS) as a fallback category.
2021-08-03 English
WANBURY LTD.has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 12/08/2021 ,inter alia, to consider and approve Notice is hereby given pursuant to ....
Regulatory Filings
2021-08-03 English

Browse filings by year

17 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.